Abstract | BACKGROUND: METHODS: Patients with stage IC-IV epithelial ovarian, peritoneal or fallopian tube cancer were enrolled at the first relapse after at least 6 months since completion of the first line treatment. Docetaxel 75 mg/m2 was given as an one hour IV infusion followed immediately by carboplatin (AUC=5) given as a 30-60 min. IV infusion on day 1 and repeated every 3 weeks for 6-9 courses. Primary endpoint was toxicity; secondary endpoints were response rate and the time to progression. RESULTS: A total of 74 patients were included. Of these, 50 patients received 6 or more cycles, 13 received 3-5 courses and 11 received less than 3 courses. A total of 398 cycles were given. Grade 3/4 neutropenia was seen in 80% (59 of 74) patients with an incidence of febrile neutropenia of 16%. Grade 2/3 sensory peripheral neuropathy occurred in 7% of patients, but no grade 4 sensory peripheral neuropathy was observed. Sixty patients were evaluable for response. The overall response rate was 70% with 28% complete responses in the response evaluable patient population. Median progression-free survival was 12.4 months (95% CI 10.4-14.4). CONCLUSIONS:
|
Authors | Yun Wang, Jørn Herrstedt, Hanne Havsteen, Rene DePoint Christensen, Mansoor Raza Mirza, Bente Lund, Johanna Maenpaa, Gunnar Kristensen |
Journal | BMC cancer
(BMC Cancer)
Vol. 14
Pg. 937
(Dec 11 2014)
ISSN: 1471-2407 [Electronic] England |
PMID | 25494701
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Taxoids
- Docetaxel
- Carboplatin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Carboplatin
(administration & dosage, adverse effects)
- Carcinoma
(drug therapy)
- Carcinoma, Ovarian Epithelial
- Chemotherapy-Induced Febrile Neutropenia
(etiology)
- Disease Progression
- Disease-Free Survival
- Docetaxel
- Drug Screening Assays, Antitumor
- Fallopian Tube Neoplasms
(drug therapy)
- Female
- Humans
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Neoplasms, Glandular and Epithelial
(drug therapy)
- Ovarian Neoplasms
(drug therapy)
- Peritoneal Neoplasms
(drug therapy)
- Prospective Studies
- Somatosensory Disorders
(chemically induced)
- Taxoids
(administration & dosage, adverse effects)
- Treatment Outcome
- Young Adult
|